South Korea Overhauls Generic Drug Pricing to Spur Innovation After 14 Years

South Korea is overhauling its pricing system for generic drugs, a move not seen in 14 years. The government's objective is to steer the pharmaceutical industry away from its heavy reliance on generics and towards innovation. This significant policy shift is poised to reshape how domestic drug manufacturers strategize for survival, impact the cost of medications for patients, and alter the framework for supplying essential medicines.

The revision, effective August 1, targets the calculation system for insurance reimbursements for generic drugs. For over a decade, the system has favored generics, leading to a market structure dominated by them. The new approach seeks to incentivize research and development of new drugs by adjusting the pricing mechanism.

Industry experts anticipate that this reform will force pharmaceutical companies to adapt by investing more in innovative drug development. Those that fail to pivot may struggle to remain competitive. The changes could also lead to a more dynamic market, potentially improving access to novel treatments for patients, though initial adjustments might affect the affordability of existing generics. The government's aim is to foster a more robust and forward-looking pharmaceutical sector.